ClinicalTrials.gg
CompletedNCT01387113PERFUSEUpdated Mar 6, 2023

The PERFusion Use in Stroke Evaluation Study

An observational study in Ischemic Stroke, sponsored by California Pacific Medical Center Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-06.

Sponsored by California Pacific Medical Center Research Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
48
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Enrollment
91st of 111
48 · median 300
Started
2011
with 16 others
Observational
111 of 480
41 open now
Registered
84th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 91st largest by enrollment of the 111 observational ones that give a count, is one of 17 that started in 2011, is one of 111 observational ones, and was the 84th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

This is an open label single center phase II trial, evaluating the utility of 64 slice CT perfusion (CTP) in acute ischemic stroke (AIS) patients. The main aim is to determine which aspects of CTP imaging can aid in expanding the time window for thrombolysis with IV (rt-PA) in AIS patients up to 6 hours after symptom onset.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • stroke
  • tPA
  • Thrombolysis
  • rt-PA
  • Ischemic
  • CTP
  • Imaging
  • CT Perfusion Imaging
  • Perfusion
  • CTA
  • CT Angiography
  • Acute ischemic stroke
  • Acute stroke therapy
  • (AIS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All acute ischemic stroke patients who present to the emergency room at CPMC who receive IV rt-PA within 6 hours of symptom onset

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute ischemic stroke
  • ≥ 18 years old
  • presentation up to 6 hours from time of onset of acute stroke symptoms

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • inability to receive CT scan
  • allergy to IV contrast
  • symptoms with full resolution
  • intracerebral hemorrhage
  • severe stroke which is classified as 'malignant' (hypodensity on noncontrast CT greater than 1/3 cerebral hemisphere)
  • premorbid mRS of >3
  • of ≤3 months
  • any condition which, in the opinion of the investigator makes the subject unsuitable for study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
48 participants (actual)

Groups and cohorts

  • Acute ischemic stroke patients

    All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset

    Other: Computed tomography perfusion imaging

Interventions

  • OtherComputed tomography perfusion imaging

    As per standard of care at CPMC

06

What researchers measure

Primary outcomes

  1. Final infarct volume

    Time frame: 24 hour post-thrombolysis

Secondary outcomes

  1. Large vessel occlusion on neuroimaging

    Time frame: 24 hours post-thrombolysis

  2. NIHSS

    Time frame: 24-hours from tPA adminsitration

  3. Symptomatic intracerebral hemorrhage post-thrombolysis

    Time frame: 24 hours post-thrombolysis

  4. Modified Rankin Scale

    Time frame: 3-months from tPA administration

07

Study locations

1 site
  • California Pacific Medical Center
    San Francisco, California 94115, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jul 2022 and a completion of Jul 2022. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2011
First posted
Jul 4, 2011
Start
May 2011
Primary completionActual
Jul 2022
CompletionActual
Jul 2022
Last update
Mar 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01387113
Lead sponsor
California Pacific Medical Center Research Institute
Collaborators
California Pacific Medical Center
Responsible party
Nobl Barazangi (Medical Doctor, California Pacific Medical Center Research Institute) — Principal investigator
First posted
Jul 4, 2011
Start date
May 2011
Primary completion
Jul 2022
Completion
Jul 2022
Last update
Mar 6, 2023

Study contacts

Nobl Barazangi, MD, PhD
principal investigator · CPMC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion